6 reports

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Blood Supply
  • Digestive System Disorder
  • Monoclonal Antibody
  • United States

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Antibiotic Resistance
  • Blood Supply
  • Cell Therapy
  • Digestive System Disorder
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Blood Supply
  • Digestive System Disorder
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Blood Supply
  • Digestive System Disorder
  • Therapy
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy Drug
  • Blood Supply
  • Digestive System Disorder
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antibiotic Resistance
  • Antifungal
  • Blood Supply
  • Digestive System Disorder
  • Monoclonal Antibody